These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16683965)

  • 1. Antiglucocoticoid treatments for depression.
    Young AH
    Aust N Z J Psychiatry; 2006 May; 40(5):402-5. PubMed ID: 16683965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cortisol in mood disorders.
    Young AH
    Stress; 2004 Dec; 7(4):205-8. PubMed ID: 16019585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
    Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I
    J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men.
    Mattsson C; Reynolds RM; Simonyte K; Olsson T; Walker BR
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1347-52. PubMed ID: 19141586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mifepristone as a therapeutic agent in psychiatry.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2013 Jun; 51(6):11-4. PubMed ID: 23814820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biological effects of mifepristone treatment for psychotic depression.
    Flores BH; Kenna H; Keller J; Solvason HB; Schatzberg AF
    Neuropsychopharmacology; 2006 Mar; 31(3):628-36. PubMed ID: 16160710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression.
    Schüle C; Baghai TC; Eser D; Rupprecht R
    Expert Rev Neurother; 2009 Jul; 9(7):1005-19. PubMed ID: 19589050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.
    Mackin P; Gallagher P; Watson S; Young AH; Ferrier IN
    Aust N Z J Psychiatry; 2007 Apr; 41(4):321-6. PubMed ID: 17464718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of the hypothalamo-pituitary-adrenal axis as a therapeutic target in anorexia nervosa.
    Bou Khalil R; Souaiby L; Farès N
    Physiol Behav; 2017 Mar; 171():13-20. PubMed ID: 28043861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis.
    Lombardo G; Enache D; Gianotti L; Schatzberg AF; Young AH; Pariante CM; Mondelli V
    Psychoneuroendocrinology; 2019 Dec; 110():104420. PubMed ID: 31499391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overnight suppression of HPA axis after mineraolocorticoid receptor stimulation: A sleep endocrine study.
    Demiralay C; Agorastos A; Jahn H; Kellner M; Yassouridis A; Wiedemann K
    Psychiatry Res; 2015 May; 227(1):65-70. PubMed ID: 25799272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?
    Kling MA; Coleman VH; Schulkin J
    Depress Anxiety; 2009; 26(7):641-9. PubMed ID: 19133699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortisol and depression: three questions for psychiatry.
    Herbert J
    Psychol Med; 2013 Mar; 43(3):449-69. PubMed ID: 22564216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis.
    Soria V; González-Rodríguez A; Huerta-Ramos E; Usall J; Cobo J; Bioque M; Barbero JD; García-Rizo C; Tost M; Monreal JA; ; Labad J
    Psychoneuroendocrinology; 2018 Jul; 93():8-19. PubMed ID: 29680774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression.
    Watson S; Gallagher P; Porter RJ; Smith MS; Herron LJ; Bulmer S; ; Young AH; Ferrier IN
    Biol Psychiatry; 2012 Dec; 72(11):943-9. PubMed ID: 22770649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological management of Cushing's syndrome: an update.
    Dang CN; Trainer P
    Arq Bras Endocrinol Metabol; 2007 Nov; 51(8):1339-48. PubMed ID: 18209872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls.
    Buckley TM; Mullen BC; Schatzberg AF
    Psychoneuroendocrinology; 2007; 32(8-10):859-64. PubMed ID: 17666187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence.
    Kakko J; von Wachenfeldt J; Svanborg KD; Lidström J; Barr CS; Heilig M
    Biol Psychiatry; 2008 Jan; 63(2):172-7. PubMed ID: 17850768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is mifepristone useful in psychotic depression?
    Carroll BJ; Rubin RT
    Neuropsychopharmacology; 2006 Dec; 31(12):2793-4; author reply 2795-7. PubMed ID: 17109015
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute stress-induced sensitization of the pituitary-adrenal response to heterotypic stressors: independence of glucocorticoid release and activation of CRH1 receptors.
    Belda X; Daviu N; Nadal R; Armario A
    Horm Behav; 2012 Sep; 62(4):515-24. PubMed ID: 22986335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.